Co-Diagnostics JV CoSara Diagnostics receives clearance from CDSCO for COVID-19 2-Gene Multiplex Test

▴ Co-Diagnostics JV CoSara Diagnostics receives clearance from CDSCO for COVID-19 2-Gene Multiplex Test
The pharma company is geared up by providing affordable, high quality, 'Made in India' 2-gene multiplex COVID-19 RT-PCR tests across the country

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced recently that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test as an in vitro diagnostic ("IVD"), intended for the qualitative detection of the SARS-CoV-2 virus.

The Saragene test kit approved by the CDSCO uses the Company's patented CoPrimer technology and is based on a test originally designed by Co-Diagnostics, who also recently announced receipt of a CE marking for its Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex test. Both the CoSara and Co-Diagnostics test target two gene markers of the SARS-CoV-2 genome, RdRp and E-gene, to identify the presence of the virus, and were designed to meet the needs of those markets where government or regulatory bodies recommend a multi-target coronavirus diagnostic.

Dwight Egan, CEO of Co-Diagnostics, commented "Tests built on our CoPrimer technology have several advantages over other platforms, including the enhanced multiplex capabilities. We believe that the highly specific nature of the new Saragene test which follows World Health Organization guidance will help CoSara be able to play an even more active role in the battle against this pandemic."

CoSara Director Mohal Sarabhai remarked "Our honorable Prime Minister Shri Narendra Modi has endorsed the hike in number of available RT-PCR tests to keep the COVID-19 positivity rate under 5%. With this clearance in place, CoSara is geared up for this challenge by providing affordable, high quality, 'Made in India' 2-gene multiplex COVID-19 RT-PCR tests across the country."

CoSara has previously received CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) to be manufactured and sold as IVDs in the Indian market.

Tags : #Co-Diagnostics #CoSaraDiagnostics #LatestNewsonCoSaraDiagnostics28thNov #LatestPharmaNews28thNov #LatestNewsonCOVIDTest #PMNarendraModi #MakeinIndia #AffordableCOVIDTest

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Priti Mehta, a Pediatric hematologist Oncologist explains the facts about Pre-implantation genetic diagnosisJanuary 21, 2021
The best way to lose weight is to not think about losing weight says Karishma Shah, Nutrition ConsultantJanuary 21, 2021
Demystifying Greenfield Pharma projects and Investment for the beginnersJanuary 21, 2021
Maharashtra COVID Update: Over 50,000 given COVID vaccine shots in three sessions so far January 21, 2021
1,12,007 beneficiaries vaccinated against Coronavirus, covering 11% health workersJanuary 21, 2021
Kerala continues to report surge in COVID cases with 6815 new casesJanuary 21, 2021
US studies claims vaccines are effective against the new Covid-19 strains January 21, 2021
Madhya Pradesh: Bird Flu virus found in 32 districts of state so farJanuary 20, 2021
Karnataka Health Minister expresses hope of launching Arogya Karnataka emergency health servicesJanuary 20, 2021
India starts shipments of Made in India COVID-19 Vaccines to neighbouring countriesJanuary 20, 2021
COVID-19 recovery rate improves to 98.13 pct in JharkhandJanuary 20, 2021
National COVID-19 recovery rate improves to 96.70 per centJanuary 20, 2021
Benefits of coconut waterJanuary 20, 2021
The RSA Group welcomes Eleanor Davies as Managing PartnerJanuary 19, 2021
Mask-wearing linked to reduced COVID-19 transmission, US modelling study suggestsJanuary 19, 2021
Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T TherapyJanuary 19, 2021
FUJIFILM Diosynth Biotechnologies begins production of two COVID-19 vaccinesJanuary 19, 2021
Fried food intake linked to heightened serious heart disease and stroke riskJanuary 19, 2021
‘’What is more dangerous is that we don't have any kind of criteria to be a coach,’’ says Parag Patil, Founder, LetzRun India, and MaxFit IndiaJanuary 19, 2021
‘’The younger generation must understand that health and fitness is at least a Forty-year commitment, and not a four-month game,’’ says Shreeharsh Deshmukh, Trainer, and Nutritionist, The Fit problemJanuary 19, 2021